Tech Company Financing Transactions
Denali Therapeutics Funding Round
Denali Therapeutics closed a $217 million financing round on 5/15/2015. Investors included Alaska Permanent Fund, Arch Venture Partners and F-Prime Capital.
Transaction Overview
Company Name
Announced On
5/15/2015
Transaction Type
Venture Equity
Amount
$217,000,000
Round
Undisclosed
Proceeds Purpose
The company will use the funds to discover and develop effective medicines for Alzheimer's disease, Parkinson's disease, ALS and other neurodegenerative diseases.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
161 Oyster Point Blvd.
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
Denali (NASDAQ: DNLI) was founded on the collaboration of leading scientists, industry experts and investors who share the vision that scientific discovery energetically applied to translational medicine is the key to delivering effective therapies to patients.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 5/15/2015: Ineda Systems venture capital transaction
Next: 5/15/2015: Silversheet venture capital transaction
Share this article
Where The Data Comes From
We record tech company VC transactions. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs